Nuvectis Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative precision medicines for serious oncology conditions with unmet medical needs. The company specializes in identifying and advancing drug candidates that target cancer-promoting factors, particularly within the SRC kinase family. Its core activities involve licensing, preclinical development, and clinical-stage testing of targeted therapies designed to inhibit key oncogenic drivers.

Nuvectis Pharma generates revenue primarily through the potential future commercialization of its product candidates, currently centered on NXP900 and previously NXP800. The company does not yet have commercial products or revenue from sales, as its candidates remain in clinical development. Revenue generation is anticipated upon regulatory approval and market launch of its therapies, which would be supported by milestone payments and royalties under its licensing agreements.

The company operates through the following segments:

• NXP900 Program: This segment encompasses the development of NXP900, a targeted small molecule drug candidate that inhibits both SRC and YES1 kinases. NXP900 is designed to induce and lock SRC in its inactive conformation, thereby blocking both catalytic and scaffolding functions of the kinase. The program has completed Phase 1a clinical trials in advanced solid tumors and initiated Phase 1b expansion to evaluate safety, tolerability, and preliminary efficacy as a monotherapy and in combination with EGFR and ALK inhibitors. NXP900 is the lead product candidate under this segment.

• NXP800 Program: This segment involved the development of NXP800, a small molecule product candidate intended for broad application across various cancers. The company entered into a worldwide exclusive license agreement with the CRT Pioneer Fund for NXP800 in May 2021. In July 2025, following completion of a Phase 1b clinical study, Nuvectis decided to cease clinical development of NXP800 and assess potential next steps for the compound. NXP800 is no longer an active development program.

Nuvectis Pharma positions itself within the competitive oncology biopharmaceutical landscape as a developer of precision medicines targeting the SRC/YES1 kinase pathway, an area with limited approved therapies. The company differentiates NXP900 from existing kinase inhibitors like Dasatinib (SPRYCEL®) and bosutinib (BOSULIF®), which inhibit only catalytic activity and show limited clinical activity in solid tumors. Nuvectis emphasizes NXP900’s dual mechanism of action and high selectivity as potential advantages in overcoming resistance and addressing metastatic disease. The company faces competition from established pharmaceutical and biotechnology firms engaged in similar kinase-targeted drug development and licensing activities.

Nuvectis Pharma serves patients with advanced solid tumors who have unmet medical needs, particularly those whose cancers exhibit SRC or YES1 pathway activation and resistance to existing therapies. The company’s clinical trials focus on indications such as breast, esophageal, head and neck, and non-small cell lung cancers, among others. Its therapeutic approach is intended for use in both monotherapy and combination settings with EGFR and ALK inhibitors, targeting patient populations seeking improved outcomes in refractory or resistant disease settings.